This prior information notice announces an open market consultation. The ANTI-SUPERBUGS pre-commercial procurement aims to improve the quality of care processes in hospital and the reduction of both the costs and the collateral effects provoked by Multi-Drug Resistant Organisms (MDROs or Superbugs) and other Health Associated Infections (HAIs) pathogens, through the development and testing of prototypes of devices and ICT services that can: (1) test non-invasively for the presence of MDROs and other pathogens, and (2) provide continuous information and remote alerts to health professionals on environmental contamination by MDROs, and other pathogens, on high contact surfaces, applicable to existing healthcare environments. This procurement receives funding from the European Commission Horizon 2020 Research and Innovation Programme (H2020-EU.2.1.1 - Grant Agreement No. 688878). The procurement will be carried out jointly by a group of buyers (subject to variations, as of the date of th

This prior information notice announces an open market consultation. The ANTI-SUPERBUGS pre-commercial procurement aims to improve the quality of care processes in hospital and the reduction of both the costs and the collateral effects provoked by Multi-Drug Resistant Organisms (MDROs or Superbugs) and other Health Associated Infections (HAIs) pathogens, through the development and testing of prototypes of devices and ICT services that can: (1) test non-invasively for the presence of MDROs and other pathogens, and (2) provide continuous information and remote alerts to health professionals on environmental contamination by MDROs, and other pathogens, on high contact surfaces, applicable to existing healthcare environments. This procurement receives funding from the European Commission Horizon 2020 Research and Innovation Programme (H2020-EU.2.1.1 - Grant Agreement No. 688878). The procurement will be carried out jointly by a group of buyers (subject to variations, as of the date of the publication of this information notice): Institut Catala d'Oncologia (Spain), Universitaetsklinikum Aachen (Germany), Sheffield Teaching Hospitals NHS Foundation Trust (United Kingdom) and Provincia Autonoma Di Trento (Italy).. The Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) will act as lead procurer and will award the contracts on behalf of the buyers group. The open market consultation will consist in: open events on 15.12.2017 at AQuAS (Barcelona), on 18.01.2018 at Improving Infection Control within Healthcare conference, University of Salford,(Manchester), on 24.1.2018 at ZENIT Headquarters (Germany), on 31.1.2018 at the Province of Trento (Italy), & a questionnaire All information regarding the open market consultation and the information provided during the consultation will be published on website (http://www.antisuperbugs.eu)